234 related articles for article (PubMed ID: 26700437)
21. Experience-based discovery (EBD) of aryl hydrazines as new scaffolds for the development of LSD1/KDM1A inhibitors.
Li ZR; Wang S; Yang L; Yuan XH; Suo FZ; Yu B; Liu HM
Eur J Med Chem; 2019 Mar; 166():432-444. PubMed ID: 30739825
[TBL] [Abstract][Full Text] [Related]
22. Molecular mimicry and ligand recognition in binding and catalysis by the histone demethylase LSD1-CoREST complex.
Baron R; Binda C; Tortorici M; McCammon JA; Mattevi A
Structure; 2011 Feb; 19(2):212-20. PubMed ID: 21300290
[TBL] [Abstract][Full Text] [Related]
23. Identification of selective and reversible LSD1 inhibitors with anti-metastasis activity by high-throughput docking.
Li L; Li R; Wang Y
Bioorg Med Chem Lett; 2019 Feb; 29(4):544-548. PubMed ID: 30611617
[TBL] [Abstract][Full Text] [Related]
24. Activation of lysine-specific demethylase 1 inhibitor peptide by redox-controlled cleavage of a traceless linker.
Amano Y; Umezawa N; Sato S; Watanabe H; Umehara T; Higuchi T
Bioorg Med Chem; 2017 Feb; 25(3):1227-1234. PubMed ID: 28065500
[TBL] [Abstract][Full Text] [Related]
25. [1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
Li ZH; Ma JL; Liu GZ; Zhang XH; Qin TT; Ren WH; Zhao TQ; Chen XH; Zhang ZQ
Eur J Med Chem; 2020 Feb; 187():111989. PubMed ID: 31881456
[TBL] [Abstract][Full Text] [Related]
26. Heterogeneous Antibody-Based Activity Assay for Lysine Specific Demethylase 1 (LSD1) on a Histone Peptide Substrate.
Schmitt ML; Ladwein KI; Carlino L; Schulz-Fincke J; Willmann D; Metzger E; Schilcher P; Imhof A; Schüle R; Sippl W; Jung M
J Biomol Screen; 2014 Jul; 19(6):973-8. PubMed ID: 24687155
[TBL] [Abstract][Full Text] [Related]
27. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
[TBL] [Abstract][Full Text] [Related]
29. Target separation and antitumor metastasis activity of sesquiterpene-based lysine-specific demethylase 1 inhibitors from zedoary turmeric oil.
Ren C; Lin Y; Liu X; Yan D; Xu X; Zhu D; Kong L; Han C
Bioorg Chem; 2021 Mar; 108():104666. PubMed ID: 33550070
[TBL] [Abstract][Full Text] [Related]
30. [Histone demethylase LSD1 and its biological functions].
Shao GB; Huang XJ; Gong AH; Zhang ZJ; Lu RZ; Sang JR
Yi Chuan; 2010 Apr; 32(4):331-8. PubMed ID: 20423886
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and biological activity of 4-(4-benzyloxy)phenoxypiperidines as selective and reversible LSD1 inhibitors.
Xi J; Xu S; Zhang L; Bi X; Ren Y; Liu YC; Gu Y; Xu Y; Lan F; Zha X
Bioorg Chem; 2018 Aug; 78():7-16. PubMed ID: 29524666
[TBL] [Abstract][Full Text] [Related]
32. High-throughput TR-FRET assays for identifying inhibitors of LSD1 and JMJD2C histone lysine demethylases.
Yu V; Fisch T; Long AM; Tang J; Lee JH; Hierl M; Chen H; Yakowec P; Schwandner R; Emkey R
J Biomol Screen; 2012 Jan; 17(1):27-38. PubMed ID: 21859682
[TBL] [Abstract][Full Text] [Related]
33. A mechanism-based inactivator for histone demethylase LSD1.
Culhane JC; Szewczuk LM; Liu X; Da G; Marmorstein R; Cole PA
J Am Chem Soc; 2006 Apr; 128(14):4536-7. PubMed ID: 16594666
[TBL] [Abstract][Full Text] [Related]
34. An Overview on Screening Methods for Lysine Specific Demethylase 1 (LSD1) Inhibitors.
Zheng YC; Chang J; Zhang T; Suo FZ; Chen XB; Liu Y; Zhao B; Yu B; Liu HM
Curr Med Chem; 2017; 24(23):2496-2504. PubMed ID: 28486922
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of phenylcyclopropylamine compounds by enzymatic assay of lysine-specific demethylase 2 in the presence of NPAC peptide.
Kakizawa T; Mizukami T; Itoh Y; Hasegawa M; Sasaki R; Suzuki T
Bioorg Med Chem Lett; 2016 Feb; 26(4):1193-5. PubMed ID: 26794039
[TBL] [Abstract][Full Text] [Related]
36. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine.
Yang M; Culhane JC; Szewczuk LM; Jalili P; Ball HL; Machius M; Cole PA; Yu H
Biochemistry; 2007 Jul; 46(27):8058-65. PubMed ID: 17569509
[TBL] [Abstract][Full Text] [Related]
37. Towards the development of activity-based probes for detection of lysine-specific demethylase-1 activity.
Ourailidou ME; Lenoci A; Zwergel C; Rotili D; Mai A; Dekker FJ
Bioorg Med Chem; 2017 Feb; 25(3):847-856. PubMed ID: 27989416
[TBL] [Abstract][Full Text] [Related]
38. CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1.
Lynch JT; Cockerill MJ; Hitchin JR; Wiseman DH; Somervaille TC
Anal Biochem; 2013 Nov; 442(1):104-6. PubMed ID: 23911524
[TBL] [Abstract][Full Text] [Related]
39. Identification of cell-active lysine specific demethylase 1-selective inhibitors.
Ueda R; Suzuki T; Mino K; Tsumoto H; Nakagawa H; Hasegawa M; Sasaki R; Mizukami T; Miyata N
J Am Chem Soc; 2009 Dec; 131(48):17536-7. PubMed ID: 19950987
[TBL] [Abstract][Full Text] [Related]
40. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1.
Schmidt DM; McCafferty DG
Biochemistry; 2007 Apr; 46(14):4408-16. PubMed ID: 17367163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
